Rodman & Renshaw is out with its report today on MannKind MNKD, maintaining Market Perform.
In its report, Rodman & Renshaw writes, "With the clinical picture coming into view and the funding to support the two Phase 3 trials unspecified, we reiterate our Market Perform rating on Mannkind. We believe the clinical trial data that the company has presented has been impressive and the market opportunity for this
Afrezza and the Dreamboat inhaler is much larger than the current valuation suggests."
At the time of posting, shares of MNKD were trading at $2.78, up 2.58% from Thursday's close.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in